Alex Gorsky.

CUMBERLAND, Rhode Island—Neurotech Pharmaceuticals, Inc., a private clinical stage biotech company, has announced that Alex Gorsky has been elected to Neurotech’s board as lead director. Gorsky is the former chairman and CEO of Johnson & Johnson. Under Gorsky’s leadership, Johnson & Johnson grew to become one of the world’s largest diversified health care companies and one of the foremost innovators in research and development for emerging health technologies. His influence has shaped both the health care landscape and the greater business community through his work as a member of the Business Roundtable, the Business Council and many industry groups.

Gorsky currently sits on the boards of Apple, IBM, JPMorgan Chase, and the Travis Manion Foundation, as well as the Wharton School of the University of Pennsylvania Board of Advisors.

“I am delighted to welcome Alex to Neurotech’s board of directors,” said Jim Mazzo, Neurotech’s executive chairman. “As a visionary in patient focused health care, his expertise and enthusiasm for innovative technology will greatly enrich Neurotech’s mission to revolutionize treatments for various ocular diseases using our encapsulated cell therapy.”

Gorsky said, “I am honored to join Neurotech’s board and look forward to using my experience to help the company navigate in a rapidly evolving environment. I am inspired by the Lowy family’s long-term commitment. This unique scientific approach and novel technology for the treatment of chronic eye diseases has the potential to provide access to important health options for patients around the world.”

Neurotech Pharmaceuticals, Inc. focuses on developing transformative therapies for chronic eye diseases.